Pyothorax-Associated Lymphoma: A Review of 106 Cases

Nakatsuka, Shin‐ichi; Yao, Masayuki; Hoshida, Yoshihiko; Yamamoto, Satoru; Iuchi, Keiji; Aozasa, Katsuyuki

doi:10.1200/jco.2002.09.021

Cited by 223 publications

(173 citation statements)

References 15 publications

Supporting

Mentioning

159

Contrasting

Unclassified

Order By: Relevance

“…MUM-1 and CD138 are positive in such cases. EBER and EBNA-2 are positive in most cases, illustrating a type III latency program [22,23]. Clonal rearrangement of the immunoglobulin gene is seen in most cases.…”

Section: Differential Diagnosismentioning

confidence: 99%

See 1 more Smart Citation

EBV‐positive diffuse large B‐cell lymphoma of the elderly: 2016 update on diagnosis, risk‐stratification, and management

et al. 2016

View full text Add to dashboard Cite

Epstein–Barr virus (EBV)‐positive diffuse large B‐cell lymphoma (DLBCL) of the elderly is a provisional entity included in the 2008 WHO classification of lymphoid neoplasms. It is a disease typically seen in the elderly and thought to be associated with chronic EBV infection and severe immunosuppression with a component of immunosenescence. Recent research, however, has suggested that EBV‐positive DLBCL can be seen in younger, immunocompetent patients.The diagnosis of EBV‐positive DLBCL of the elderly is made through a careful pathological evaluation. The differential diagnosis includes infectious mononucleosis (specifically in younger patients), lymphomatoid granulomatosis, Hodgkin lymphoma, and gray zone lymphoma, among others. Detection of EBV‐encoded RNA (EBER) is considered standard for diagnosis; however, a clear cutoff for positivity has not been defined.The International Prognostic Index (IPI), and the Oyama score can be used for risk‐stratification. The Oyama score includes age >70 years and presence of B symptoms. The expression of CD30 is emerging as a potential adverse, and targetable, prognostic factor.Patients with EBV‐positive DLBCL should be staged and managed following similar guidelines than patients with EBV‐negative DLBCL. It has been suggested, however, that EBV‐positive patients have a worse prognosis than EBV‐negative counterparts in the era of chemoimmunotherapy. There is an opportunity to study and develop targeted therapy in the management of patients with EBV‐positive DLBCL. Am. J. Hematol. 91:530–537, 2016. © 2016 Wiley Periodicals, Inc.

show abstract

Section: Differential Diagnosismentioning

confidence: 99%

“…By gene expression profiling, PAL was shown to be molecularly different from nodal DLBCL, with increased expression of activated B-cell-like signature [26]. DLBCL associated with chronic inflammation is an aggressive lymphoma, with 5-year survival rate of 22% [22].…”

Section: Differential Diagnosismentioning

confidence: 99%

EBV‐positive diffuse large B‐cell lymphoma of the elderly: 2016 update on diagnosis, risk‐stratification, and management

et al. 2016

View full text Add to dashboard Cite

show abstract

“…These are rare tumors, occurring in the setting of human immunodeficiency virus infection (PEL and plasmablastic lymphoma of the oral cavity) and in immunocompetent patients (ALK-positive DLBCL and pyothorax-associated lymphomas 59,60 ). Recent reviews on B-cell lymphomas with plasmablastic differentiation and acquired immunodeficiency syndrome-related lymphomas have been written and can be recommended.…”

Section: Dlbcl With Plasmablastic Morphologymentioning

confidence: 99%

Diffuse large B-cell lymphoma: a heterogeneous group of non-Hodgkin lymphomas comprising several distinct clinicopathological entities

2006

View full text Add to dashboard Cite

Diffuse large B-cell lymphoma (DLBCL) as defined by the World Health Organization (WHO) classification is clinically, morphologically and genetically a heterogeneous group of malignant proliferations of large lymphoid B cells. Over the last 6 years, several studies have been published improving our understanding of these lymphomas. These studies analyzed DLBCL by their gene expression profile, provided further information on some of the variants of DLBCL listed in the WHO classification and stressed the impact of the site of origin of these tumors. This review summarizes these recent data and explores their impact on the recognition of new clinicopathological lymphoma entities.

show abstract

“…Indeed, PAL develops in patients with more than 20 years' history of chronic pyothorax. 1,2) Defects of the genes maintaining genome stability might occur in the tumorigenesis of PAL.…”

Section: Discussionmentioning

confidence: 99%

Establishment and characterization of unique cell lines derived from pyothorax‐associated lymphoma which develops in long‐standing pyothorax and is strongly associated with Epstein‐Barr virus infection

et al. 2003

Self Cite

View full text Add to dashboard Cite

show abstract

Pyothorax-Associated Lymphoma: A Review of 106 Cases

Cited by 223 publications

References 15 publications

EBV‐positive diffuse large B‐cell lymphoma of the elderly: 2016 update on diagnosis, risk‐stratification, and management

EBV‐positive diffuse large B‐cell lymphoma of the elderly: 2016 update on diagnosis, risk‐stratification, and management

Diffuse large B-cell lymphoma: a heterogeneous group of non-Hodgkin lymphomas comprising several distinct clinicopathological entities

Establishment and characterization of unique cell lines derived from pyothorax‐associated lymphoma which develops in long‐standing pyothorax and is strongly associated with Epstein‐Barr virus infection

Contact Info

Product

Resources

About